» Articles » PMID: 36167556

Alamandine Alleviated Heart Failure and Fibrosis in Myocardial Infarction Mice

Overview
Journal Biol Direct
Publisher Biomed Central
Specialty Biology
Date 2022 Sep 27
PMID 36167556
Authors
Affiliations
Soon will be listed here.
Abstract

Alamandine (Ala) is the newest identified peptide of the renin-angiotensin system and has protective effect on myocyte hypertrophy. However, it is still unclear whether Ala can alleviate heart failure (HF). The aim of this study was to explore the effects of Ala on HF and the related cardiac fibrosis, and to probe the mechanism. HF model was induced by myocardial infarction (MI) in mice. Four weeks after MI, Ala was administrated by intraperitoneal injection for two weeks. Ala injection significantly improved cardiac dysfunction of MI mice in vivo. The cardiac fibrosis and the related biomarkers were attenuated after Ala administration in HF mice in vivo. The increases of collagen I, alpha-smooth muscle actin and transforming growth factor-beta induced by oxygen-glucose deprivation (OGD) in neonatal rat cardiac fibroblasts (NRCFs) were inhibited by Ala treatment in vitro. The biomarkers of apoptosis were elevated in NRCFs induced by OGD, which were attenuated after treating with Ala in vitro. The enhancement of oxidative stress in the heart of MI mice or in the NRCFs treated with OGD was suppressed by treating with Ala in vivo and in vitro. These effects of Ala were reversed by tBHP, an exogenous inducer of oxidative stress in vitro. These results demonstrated that Ala could alleviate cardiac dysfunction and attenuate cardiac fibrosis via inhibition of oxidative stress.

Citing Articles

Counter-regulatory RAS peptides: new therapy targets for inflammation and fibrotic diseases?.

Avila-Martinez D, Mixtega-Ruiz W, Hurtado-Capetillo J, Lopez-Franco O, Flores-Munoz M Front Pharmacol. 2024; 15:1377113.

PMID: 38666016 PMC: 11044688. DOI: 10.3389/fphar.2024.1377113.


Progress in the treatment of diabetic cardiomyopathy, a systematic review.

Shou Y, Li X, Fang Q, Xie A, Zhang Y, Fu X Pharmacol Res Perspect. 2024; 12(2):e1177.

PMID: 38407563 PMC: 10895687. DOI: 10.1002/prp2.1177.


Novel Insights into the Cardioprotective Effects of the Peptides of the Counter-Regulatory Renin-Angiotensin System.

Gamino-Gutierrez J, Teran-Hernandez I, Castellar-Lopez J, Villamizar-Villamizar W, Osorio-Llanes E, Palacios-Cruz M Biomedicines. 2024; 12(2).

PMID: 38397857 PMC: 10887066. DOI: 10.3390/biomedicines12020255.


Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.

Swiderski J, Kate Gadanec L, Apostolopoulos V, Moore G, Kelaidonis K, Matsoukas J Biomolecules. 2023; 13(5).

PMID: 37238657 PMC: 10216788. DOI: 10.3390/biom13050787.


Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention.

Yin X, Yin X, Pan X, Zhang J, Fan X, Li J Front Pharmacol. 2023; 14:1070973.

PMID: 37056987 PMC: 10086160. DOI: 10.3389/fphar.2023.1070973.

References
1.
Wong R, Steenbergen C, Murphy E . Mitochondrial permeability transition pore and calcium handling. Methods Mol Biol. 2011; 810:235-42. PMC: 3461591. DOI: 10.1007/978-1-61779-382-0_15. View

2.
Lagonegro P, Rossi S, Salvarani N, Lo Muzio F, Rozzi G, Modica J . Synthetic recovery of impulse propagation in myocardial infarction via silicon carbide semiconductive nanowires. Nat Commun. 2022; 13(1):6. PMC: 8748722. DOI: 10.1038/s41467-021-27637-2. View

3.
Silva M, de Souza-Neto F, de Jesus I, Goncalves G, Santuchi M, Sanches B . Alamandine improves cardiac remodeling induced by transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol. 2020; 320(1):H352-H363. DOI: 10.1152/ajpheart.00328.2020. View

4.
Dash S, Chattopadhyay S, Ghosh T, Dash S, Tripathy S, Das B . Self-assembled betulinic acid protects doxorubicin induced apoptosis followed by reduction of ROS-TNF-α-caspase-3 activity. Biomed Pharmacother. 2015; 72:144-57. DOI: 10.1016/j.biopha.2015.04.017. View

5.
Porter K, Turner N . Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009; 123(2):255-78. DOI: 10.1016/j.pharmthera.2009.05.002. View